Efficacy and Safety of Jaktinib in Patients With Severe Novel Noronavirus Pneumonia
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This study adopts a randomized, double-blind, placebo parallel control design, and is
expected to include 168 eligible patients with severe novel coronavirus pneumonia.